Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Summary

This study is a Phase 1b, single-center, open-label, dose-finding trial designed to identify the Recommended Phase 2 Dose (RP2D) of STI 6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with any advanced solid tumor. The patients that will be treated with STI-6129 in this trial are advanced solid tumor patients who have received prior lines of treatment.

Timeline

Start

2023-03

Primary completion

2025-08

Completion

2025-10

Drugs

Indications